



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 1 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 1. Identification

GHS product identifier : Dacarbazine for Injection, USP

Other means of identification : Not available.

Product type : Powder.

Relevant identified uses of the substance or mixture and uses advised against

Product use : Pharmaceuticals. (For intended use only.)
Observe technical data sheet/instructions for use.
Specific Treatments: Anticancer / Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.

Area of application : Professional applications.

Supplier's details : Meitheal Pharmaceuticals, Inc.
8700 W. Bryn Mawr, Suite 600S
Chicago, IL 60631

Telephone: 224-443-4617
www.meithealpharma.com

e-mail address of person responsible for this SDS : info@meithealpharma.com

Emergency telephone number (with hours of operation) : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

Section 2. Hazards identification

OSHA/HCS status : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Classification of the substance or mixture :

	COMBUSTIBLE DUSTS
H302	ACUTE TOXICITY (oral) - Category 4
H312	ACUTE TOXICITY (dermal) - Category 4
H332	ACUTE TOXICITY (inhalation) - Category 4
H315	SKIN IRRITATION - Category 2
H319	EYE IRRITATION - Category 2A
H340	GERM CELL MUTAGENICITY - Category 1
H350	CARCINOGENICITY - Category 1A
H361	TOXIC TO REPRODUCTION - Category 2
H335	SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3

Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity:
42.1%

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 2 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 2. Hazards identification

GHS label elements

Hazard pictograms

:



Signal word

: Danger

Hazard statements

: H302 + H312 + H332 - Harmful if swallowed, in contact with skin or if inhaled.
H315 - Causes skin irritation.
H319 - Causes serious eye irritation.
H335 - May cause respiratory irritation.
H340 - May cause genetic defects.
H350 - May cause cancer.
H361 - Suspected of damaging fertility or the unborn child.
May form combustible dust concentrations in air.

Precautionary statements

Prevention

: P201 - Obtain special instructions before use.
P202 - Do not handle until all safety precautions have been read and understood.
P280 - Wear protective gloves, protective clothing and eye or face protection.
P271 - Use only outdoors or in a well-ventilated area.
P261 - Avoid breathing dust or mist.
P270 - Do not eat, drink or smoke when using this product.
P264 - Wash thoroughly after handling.

Response

: P308 + P313 - IF exposed or concerned: Get medical advice or attention.
P304 + P340, P312 - IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or doctor if you feel unwell.
P301 + P312, P330 - IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell. Rinse mouth.
P302 + P312, P352 - IF ON SKIN: Call a POISON CENTER or doctor if you feel unwell. Wash with plenty of water.
P332 + P313 - If skin irritation occurs: Get medical advice or attention.
P362 + P364 - Take off contaminated clothing and wash it before reuse.
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 - If eye irritation persists: Get medical advice or attention.

Storage

: P405 - Store locked up.
P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.

Disposal

: P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

Supplemental label elements

: Keep container tightly closed. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Prevent dust accumulation.

Hazards not otherwise classified

: None known.

Hazards identified when used

: No known significant effects or critical hazards.

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 3 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 3. Composition/information on ingredients

Substance/mixture : Mixture
Other means of identification : Not available.

Ingredient name	Synonyms	%	Identifiers
citric acid	Citric acid	≥30 - ≤60	CAS: 77-92-9
dacarbazine	-	≥30 - ≤60	CAS: 4342-03-4
D-mannitol	Mannitol	≥10 - ≤30	CAS: 69-65-8

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Section 4. First aid measures

Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. If necessary, call a poison center or physician. Wash clothing before reuse. Clean shoes thoroughly before reuse.
- Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 4 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 4. First aid measures

Potential acute health effects

- Eye contact** : Causes serious eye irritation.
- Inhalation** : Harmful if inhaled. May cause respiratory irritation.
- Skin contact** : Harmful in contact with skin. Causes skin irritation.
- Ingestion** : Harmful if swallowed.

Over-exposure signs/symptoms

- Eye contact** : Adverse symptoms may include the following:
 - pain or irritation
 - watering
 - redness
- Inhalation** : Adverse symptoms may include the following:
 - respiratory tract irritation
 - coughing
 - reduced fetal weight
 - increase in fetal deaths
 - skeletal malformations
- Skin contact** : Adverse symptoms may include the following:
 - irritation
 - redness
 - reduced fetal weight
 - increase in fetal deaths
 - skeletal malformations
- Ingestion** : Adverse symptoms may include the following:
 - reduced fetal weight
 - increase in fetal deaths
 - skeletal malformations

Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 5 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 5. Fire-fighting measures

Extinguishing media

Suitable extinguishing media : Use dry chemical powder.

Unsuitable extinguishing media : Do not use water jet.

Specific hazards arising from the chemical : May form explosible dust-air mixture if dispersed.

Hazardous thermal decomposition products : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides

Special protective actions for fire-fighters : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.

Special protective equipment for fire-fighters : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing dust. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

Environmental precautions : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill : Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Avoid dust generation. Do not dry sweep. Vacuum dust with equipment fitted with a HEPA filter and place in a closed, labeled waste container. Place spilled material in a designated, labeled waste container. Dispose of via a licensed waste disposal contractor.

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 6 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 6. Accidental release measures

- Large spill** : Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Avoid dust generation. Do not dry sweep. Vacuum dust with equipment fitted with a HEPA filter and place in a closed, labeled waste container. Avoid creating dusty conditions and prevent wind dispersal. Dispose of via a licensed waste disposal contractor.

Section 7. Handling and storage

Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing dust. Avoid the creation of dust when handling and avoid all possible sources of ignition (spark or flame). Prevent dust accumulation. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Electrical equipment and lighting should be protected to appropriate standards to prevent dust coming into contact with hot surfaces, sparks or other ignition sources. Take precautionary measures against electrostatic discharges. To avoid fire or explosion, dissipate static electricity during transfer by grounding and bonding containers and equipment before transferring material. Empty containers retain product residue and can be hazardous. Do not reuse container.

- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

- Conditions for safe storage, including any incompatibilities** : Store between the following temperatures: 2 to 8°C (35.6 to 46.4°F). Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
citric acid	None.
dacarbazine	None.
D-mannitol	None.

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 7 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 8. Exposure controls/personal protection

Biological exposure indices

None known.

Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles. If operating conditions cause high dust concentrations to be produced, use dust goggles.

Skin protection

Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 8 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

Physical state	: Solid. [Powder. / Cake. (Lyophilized)]				
Color	: White. / Ivory				
Odor	: Not available.				
Odor threshold	: Not available.				
pH	: 3 to 4 [Conc. (% w/w): 1%] [Reconstitution solution]				
Melting point	: Not available.				
Boiling point or initial boiling point and boiling range	: Not available.				
Flash point	: Not applicable.				
Evaporation rate	: Not available.				
Flammability	: Not available.				
Lower and upper explosion limit/flammability limit	: Not applicable.				
Vapor pressure	: Not available.				
Relative vapor density	: Not applicable.				
Relative density	: Not available.				
Density	: Not available.				
Solubility(ies)	<table><tr><th>Media</th><th>Result</th></tr><tr><td>water</td><td>Soluble</td></tr></table>	Media	Result	water	Soluble
Media	Result				
water	Soluble				

Miscible with water	: Yes.
Partition coefficient: n-octanol/water	: Not applicable.
Auto-ignition temperature	: Not applicable.
Decomposition temperature	: Not available.
SADT	: Not available.
Viscosity	: Dynamic (room temperature): Not available. Kinematic (room temperature): Not available. Kinematic (40°C (104°F)): Not available.

Particle characteristics

Median particle size	: Not available.
-----------------------------	------------------

Other information

Physical/chemical properties comments	: No additional information.
--	------------------------------

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 9 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 10. Stability and reactivity

- Reactivity** : No specific test data related to reactivity available for this product or its ingredients.
- Chemical stability** : The product is stable.
- Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.
Under normal conditions of storage and use, hazardous polymerization will not occur.
- Conditions to avoid** : Avoid the creation of dust when handling and avoid all possible sources of ignition (spark or flame). Take precautionary measures against electrostatic discharges. To avoid fire or explosion, dissipate static electricity during transfer by grounding and bonding containers and equipment before transferring material. Prevent dust accumulation.
- Incompatible materials** : Reactive or incompatible with the following materials:
oxidizing materials
- Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	
citric acid	Rat - Oral - LD50 3 g/kg	
	Rat - Male, Female - Dermal - LD50 >2000 mg/kg	OECD [Acute Dermal Toxicity]
dacarbazine	Rat - Oral - LD50 2147 mg/kg	<u>Toxic effects:</u> Behavioral - Changes in motor activity (specific assay) Behavioral - Antipsychotic
D-mannitol	Rat - Oral - LD50 13500 mg/kg	

Conclusion/Summary [Product] : Not available.

Skin corrosion/irritation

Product/ingredient name	Result
-------------------------	--------



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 10 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 11. Toxicological information

citric acid

Rabbit - Skin - Mild irritant

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 500 mg

Rabbit - Skin - Moderate irritant

Amount/concentration applied: 0.5 Ml

Conclusion/Summary [Product] : Not available.

Serious eye damage/eye irritation

Product/ingredient name

citric acid

Result

Rabbit - Eyes - Severe irritant

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 750 ug

Conclusion/Summary [Product] : Not available.

Respiratory corrosion/irritation

Conclusion/Summary [Product] : Not available.

Respiratory or skin sensitization

Skin

Conclusion/Summary [Product] : Not available.

Respiratory

Conclusion/Summary [Product] : Not available.

Germ cell mutagenicity

Conclusion/Summary [Product] : Not available.

Carcinogenicity

Conclusion/Summary [Product] : Not available.

Classification



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 11 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 11. Toxicological information

Product/ingredient name	OSHA	IARC	NTP
dacarbazine	-	2B	Reasonably anticipated to be a human carcinogen.

Reproductive toxicity

Conclusion/Summary [Product] : Not available.

Specific target organ toxicity (single exposure)

Product/ingredient name

citric acid

dacarbazine

Result

SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE)
(Respiratory tract irritation) - Category 3

SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE)
(Respiratory tract irritation) - Category 3

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure

Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.

Potential acute health effects

Eye contact

: Causes serious eye irritation.

Inhalation

: Harmful if inhaled. May cause respiratory irritation.

Skin contact

: Harmful in contact with skin. Causes skin irritation.

Ingestion

: Harmful if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact

: Adverse symptoms may include the following:
pain or irritation
watering
redness

Inhalation

: Adverse symptoms may include the following:
respiratory tract irritation
coughing
reduced fetal weight
increase in fetal deaths
skeletal malformations

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 12 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 11. Toxicological information

- Skin contact** : Adverse symptoms may include the following:
irritation
redness
reduced fetal weight
increase in fetal deaths
skeletal malformations
- Ingestion** : Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

Conclusion/Summary [Product] : Not available.

- General** : Repeated or prolonged inhalation of dust may lead to chronic respiratory irritation.
- Carcinogenicity** : May cause cancer. Risk of cancer depends on duration and level of exposure.
- Mutagenicity** : May cause genetic defects.
- Reproductive toxicity** : Suspected of damaging fertility or the unborn child.

Numerical measures of toxicity

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
Dacarbazine for Injection, USP	1017.7	1814.0	N/A	N/A	2.1
citric acid	3000	2500	N/A	N/A	N/A
dacarbazine	500	1100	N/A	N/A	1.5
D-mannitol	13500	N/A	N/A	N/A	N/A

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 13 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 12. Ecological information

Toxicity

Product/ingredient name

citric acid

Result
Acute - LC50 - Marine water

Crustaceans - Green crab - *Carcinus*
maenas - Adult

160 mg/l [48 hours]

Effect: Mortality

Conclusion/Summary [Product]

: Not available.

Persistence and degradability

Conclusion/Summary [Product]

: Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
citric acid	-	-	Readily

Bioaccumulative potential

Product/ingredient name	LogP_{ow}	BCF	Potential
citric acid	-1.8	-	Low
dacarbazine	-0.24	-	Low
D-mannitol	-3.1	-	Low

Mobility in soil

Soil/Water partition coefficient

: Not available.

Other adverse effects

No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods

: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 14 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 14. Transport information

	DOT Classification	IMDG	IATA
UN number	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-
Transport hazard class(es)	-	-	-
Packing group	-	-	-
Environmental hazards	No.	No.	No.

Additional information

Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments : Not available.

Section 15. Regulatory information

U.S. Federal regulations : **TSCA 8(a) CDR Exempt/Partial exemption:** Not determined
United States inventory (TSCA 8b): All components are active or exempted.

TSCA 12(b) - Chemical export notification

Not applicable.

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) : Not listed

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 15 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 15. Regulatory information

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

Classification : COMBUSTIBLE DUSTS
ACUTE TOXICITY (oral) - Category 4
ACUTE TOXICITY (dermal) - Category 4
ACUTE TOXICITY (inhalation) - Category 4
SKIN IRRITATION - Category 2
EYE IRRITATION - Category 2A
GERM CELL MUTAGENICITY - Category 1
CARCINOGENICITY - Category 1A
TOXIC TO REPRODUCTION - Category 2
SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3

Composition/information on ingredients

Name	%	Classification
citric acid	≥30 - ≤60	SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2A SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3
dacarbazine	≥30 - ≤60	ACUTE TOXICITY (oral) - Category 4 ACUTE TOXICITY (dermal) - Category 4 ACUTE TOXICITY (inhalation) - Category 4 SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2A GERM CELL MUTAGENICITY - Category 1B CARCINOGENICITY - Category 1A TOXIC TO REPRODUCTION - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3

SARA 313

Not applicable.

State regulations

Massachusetts : The following components are listed: DACARBAZINE

New York : The following components are listed: Dacarbazine

New Jersey : None of the components are listed.

Pennsylvania : The following components are listed: 1H-IMIDAZOLE-4-CARBOXAMIDE, 5-(3,3-DIMETHYL-1-TRIAZENYL)-

California Prop. 65

WARNING: This product can expose you to Dacarbazine, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 16 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 15. Regulatory information

Ingredient name	No significant risk level	Maximum acceptable dosage level
Dacarbazine	Yes.	-

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Section 16. Other information

Hazardous Material Information System (U.S.A.)

Health	*	2
Flammability		3
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

National Fire Protection Association (U.S.A.)



Procedure used to derive the classification

SDS Title: Dacarbazine for Injection, USP Safety Data Sheet	SDS Number: SDS-000085	Page Number: Page 17 of 17
Function: Regulatory Affairs	Effective Date: April 09, 2026	Version number: 2.0

Section 16. Other information

Classification	Justification
COMBUSTIBLE DUSTS ACUTE TOXICITY (oral) - Category 4 ACUTE TOXICITY (dermal) - Category 4 ACUTE TOXICITY (inhalation) - Category 4 SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2A GERM CELL MUTAGENICITY - Category 1 CARCINOGENICITY - Category 1A TOXIC TO REPRODUCTION - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3	On basis of test data Calculation method Calculation method Calculation method Calculation method Calculation method Calculation method Calculation method Calculation method Calculation method

History

Date of issue/Date of revision	: 04/09/2026
Date of previous issue	: 04/10/2024
Version	: 2.0
Prepared by	: Sphera Solutions
Key to abbreviations	: ATE = Acute Toxicity Estimate : BCF = Bioconcentration Factor : GHS = Globally Harmonized System of Classification and Labelling of Chemicals : IATA = International Air Transport Association : IBC = Intermediate Bulk Container : IMDG = International Maritime Dangerous Goods : IMO = International Maritime Organization : LogPow = logarithm of the octanol/water partition coefficient : MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) : N/A = Not available : SGG = Segregation Group : TDG = Transportation of Dangerous Goods : UN = United Nations
References	: HCS (U.S.A.)- Hazard Communication Standard : International transport regulations

Indicates information that has changed from previously issued version.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.